Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe Brilacidin had shown promise as an optical bacterial infection treatment some time ago. Think of all the people that have lost their sight due to these infections and the additional people that have lost their eyesight due to fungal infections since that time.
Makes one wonder why the optical world of medicine (to include patient groups looking for answers to eye loss issues) hasn't been pushing to further study B in this area for some years now? Something is wrong w/ the system for a possible savior for millions of people to save their eyesight has been sitting on the shelf for these many years.
It can't be left strictly to BP as their main interest is making money, not helping patients, which falls further down the list of priorities IMO.
Same goes for Kevetrin and the potential it showed for retinoblastoma cancer treatment in babies and very young children. Lots of pain, suffering, and eyesight loss when a possible very effective treatment may have been right around the corner. I am sure many parents of babies with retino.... would have risked their child being treated w/ Kevetrin to try and save their sight, especially with the outstanding safety profile K showed in clinical testing.
Just an opinion.
Blindness is one of my greatest fears in life and for Brilacidin to have shown excellent results in combating fungal keratitis, an infection of the cornea, and may be able to save 75% of the 1.5MM people a year that get it from going blind is astoundingly wonderful. I will take this as my XMAS gift this year if it can save even one person from going blind.
To show it working with other current treatments against a broad spectrum of fungal infections is also quite amazing and is an indication to me that Brilacidin can no longer be kept under wraps as perhaps one of the greatest drug breakthroughs in the history of medicine.
So why do more studying if they already know that the current authorized fungal treatments work to some extent and together with B they work to a far greater extent, knowing that Brilacidin has already done well in a ABSSSI clinical trial showing no ill effects.
People are dying from this as we speak so why not allow Compassionate Use and see if some far greater percentage survive compared to the current treatment only? Nothing to lose, everything to gain.
I don't think at the current time IPIX has the needed funds to file such a lawsuit. Maybe someday, but not soon IMO. Right now our funds availability is at the survival level and there is nothing left for anything else and I mean NOTHING.
I am not that up on the best brokerage houses to use. I have had an E+Trade for many years which now is part of Morgan Stanley and have never had trouble with my ROTH with them or recharacterizing from a regular IRA to a ROTH.
I think most of the big houses are pretty much the same but others could probably provide much better information.
Right now one could recharacterize 500K shares of IPIX into a non-taxable ROTH and only have to pay taxes now on the $10,000 or so value they currently have. If the BMed goes as planned or the B platform ever takes off the tax savings would be quite large. At the worst you would have made a small mistake even if IPIX tanked. Something to think about, especially for younger investors.
Have heard from a contact I find highly credible that there is NO association between BMed/IPIX other than ONLY as an investment in the laser technology. No Brilacidin involvement whatsoever - take it for what it's worth.
not so boggling if one thinks there are nefarious lobbyist loyalties at work regarding BP
Don't see why it would not be a treatment as it sounds like it should be the best solution for the trickiest of laser surgeries.
Worm can turn at any time and I believe 2023 is the year IPIX changes its pattern.
I wouldn't mind a very slow and very small retreat in price between now and end of year so that I can fill a lot of my wife's ROTH with cheap IPIX sharesvery early in Jan. I could then wait for later in the quarter to see if BMed advances more or other news comes about to pop the share price. At that time I could sell a wad of my cash acct shares (I have more than enough shares already for my purposes) to sell at more than I paid for my 2023 ROTH shares so effectively I moved quite a stash of shares from a cash acct to a tax free acct without having to have put in any extra money. Don't want to sell the shares now as price may go up a bit (resulting in a possible nice percentage gain) during Dec and why take the chance that happens? I actually took a few orders off the board this morning right at opening upon seeing the BMed information.
For those that have IPIX in a regular IRA and want to recharacterize them onto a ROTH IRA look into this now!! It could save you a TON of taxes should IPIX do anywhere near well and you could recharacterize at next to nothing now so your immediate tax burden wouldn't go up that much. Definitely worth looking into.
40 - 42%
Today's market reaction to the good news from B Med is as to be expected; increase the volume and drop the price to make it look like the news is not that important. But in reality, it is, and those betting against IPIX know it!!
My question as to the new laser technology is if it is "laser for dummies" good and all will be able to master it just as they do CAT scans or if it requires the skill of the doctor to employ it correctly, more like a surgeon with some being far superior to others. Hope it is dumbed down so that everyone using it will be able to treat their patients with the best care possible. Also wondering how long is the learning curve to master this new technology. Would send a msg to BMed but haven't had any luck with them answering any questions to date and don't expect a change.
If/When the laser technology becomes commercial IMO the whole financial situation for IPIX changes. They will then have access to money (by selling B Med shares as needed) and the shorts will realize they cannot drive IPIX into financial ruin. It will give IPIX the time for B to fully develop, may even allow them to take some applications direct. Such financial improvement may stop BP low balling with their offers and get B moving quickly.
The extremely successful history of both B Med founders and their history of medical device successes IMO led to this fast forwarding thru the FDA system.
We can't get anywhere near .80 unless some actual commercial application comes about, we get a BP partner that pays a good amount upfront, or some other deal comes about. This could range from the military making the B wide spectrum viral spray a mainstay for our troops (which would bring out other worldwide use of the product IMO, something comes about in South America using B as an anti-fungal in conjunction with other such drugs (they had an invitro test that showed it working with a current leading anti-fungal against a widespread problem at the current time that raised the cure rate from 50% to 95% and maybe this comes about quickly as more than a million people worldwide are dying of fungal infections), fast advancement of the BeaMed laser technology comes about, something in regards to Covid use sneaks back in due to positive effects found in Compassionate Use patients, etc.
If any of the above takes place and B finally advances out of the lab then the share price could climb rapidly. Hope springs eternal ...
Right now future is not that bright with nothing but furher investigating of B occurring but things are on the table that could change that drastically.
When Polymedix went under Brilacidin had only been in one trial and they gave too high a dose resulting in high blood pressure problems. So at the time there was very little to go on for BP to buy it. Not the case now w/ B having shown a strong backbone of anti-fungal, anti-biotic, antiviral, and anti-inflammatory properties in addition to many more factors that build on the basic broad spectrum capabilities of the aforementioned properties.
So many opportunities in large revenue areas yet no BP has thought it a good investment to give a decent deal to acquire B. Doesn't add up.
Thank you for that information; may be why we see action quicker than I have expected.
I continue to get riled by how clinical trials are handled by the FDA and the medical community at large. Due to the time it takes to construct a trial, get it passed thru the system, get hospitals and patients, and have valid objectives it all seems to be aimed at making a successful trial as difficult and costly as possible.
Since it is a new drug being tested, obviously the drug dosage and dosings are only a shot in the dark based on very preliminary data, objectives are again only estimated results that are ballpark guesses, and many other variables are unknown at the start.
It seems to me that there should be a pre-trial(s) based on a handful of patients, not the 100+ patients needed in actual trials, that would give a better indication as to how the actual trial should be structured. If say 15 patients or so are given the drug and no positive effects are found yet no negative are found either, than test another 15 with a higher dosage or more dosings. I realize this should be found out in the P1 trial but obviously that did not work in the B-CV trial as the Compassionate Use dosage was allowed higher than the trial dosage and more dosings were allowed after the first wave of trial patients were only give a 3 day dosing and later patients received a 5 day dosing and that proved advantageous (yet the 3 day dosing results still were included in the overall trial results).
By doing these ongoing adjustments you may need 50 patients but the time frame between adjustments would be only weeks, not the many, many months or year+ needed for a whole new trial.
As it stands today, there are just too many variables in a trial to justify the millions needed to run them when a single variable error could undermine the entire results. Seems to be that money and time mean nothing to those medical agencies controlling niew drugs, treatments, and devices.
Yet the BPs were able to bring a number of new vaccines on board within months, though the trial results seem to be so much harder to get they haven't been released yet.
As with all government now, I don't trust them as far as I can throw them.
I would have thought some BP already would have given IPIX a decent deal, not a great deal but not a rape deal either, to lock up the whole B package. Why wait for it to become a possible free-for-all in a bidding war should results keep coming in strong? Investors in IPIX will make out quite nicely if just a decent deal is signed.
This continual investigation of Brilacidin by all concerned agencies of the govt (DOD, BARDA, FDA, INH, etc) and international studies of B as an agent against fungal infections has been milked long enough in my opinion and now borders on pure BS.
The govt allowed the new Pfizer vaccine shot to be given to children when it hadn't been tested on any humans, the few mice it did test on showed no positive response, Pfizer hasn't revealed any test data even though called out by John Hopkins U, and yet it is commercially being sold as we speak. Does money from the BPs speak when they spread it to the right people in govt? Appears so to a high degree.
PR showed the positives of B in the recent P2 trial after it was switched to a 5 day treatment and for use as a Compassionate Use treatment. The main fault was that the trial was conceived and executed as a complete POS as it targeted the wrong sector of patients, the patients had almost a uniform taking of other medications that blocked B, the dosage was too low, and not enough dosings were given. If this was a surgical procedure, they would have operated on the wrong leg. Who is to fault for this? Obviously both IPIX for allowing the trial to proceed and the FDA for handcuffing the trial before it even started. Gee, wonder if money had anything to do with that? LOL.
So today a million + patients are dying per year of fungal infections, superbugs are immune to current antibiotics, people are dying daily from Covid, and the other host of viruses that have been studied over the last year are still killing people daily and yet where is there any hint of actually using B on these groups to see if people can actually be saved NOW???
Until we get action this investigational milking for dollars is all so much hot air to me. I am beginning to think that the medical establishment could care less about the patients. We already knew this was the feeling by government but some medical experts should have some degree of ethics I would think.
Some posts have mentioned B working against the flu. I am sure prior posts stated that B was not effective against the flu. Hope they were wrong
Once we get the DOD nasal spray what kind of clinical trial should we expect? Is the spray meant to prevent the virus from taking hold, and if so, how would they measure the effectiveness? Or is the spray meant to be given after the first sign of viral contact ? Is it a preventative or a first response treatment?
And yet the price is down. Markets don't work this way.
The ABSSSI trial proved that Brilacidin worked effectively as an antibacterial agent against infections in a very safe manner. The recent testing at U of Sao Paulo showed when combined with an already approved anti-fungal drug that the effective cure rate was 95%.
So with all the deaths and suffering to many South Americans happening now why don't they approve the combo IV (I take it that is the normal delivery vehicle) to be given on a Compassionate Use basis in that area of the world?
It can't do the sufferers any harm and if it works in vivo like it does in vitro then many, many lives would be saved now.
Attached is a leading article online under Fox News. It is in regards to major fungal threat / increase in US as a result of Covid:
https://www.foxnews.com/health/potentially-deadly-fungal-infections-climb-during-covid-pandemic-who-says
I don't see a great need to build a company as what they are going to have is basically a software program. They should lease out the program worldwide and get paid a set fee each time it is used like I imagine is done with catscan machines.
A money making machine that keeps pumping out golden eggs everyday. Would have tremendous dividend potential as next to no costs once the program is perfected with very, very few employees and next to no need for a physical facility. IPIX should make a fortune in dividends.
Anyway, that is how I hope it plays out.
I took the PR to mean the BeaMed system would be starting in UK Q1 2023. If it means only that the UK system is going to be started and not the BeaMed system than I can understand where you are coming from. Doesn't sound like the UK system has had all that much testing so maybe they will allow the BM system to go into effect soon after that since the BM system has more advantageous features than does the UK.
And as regular as clockwork the share price drops on positive news. Who'd a thunk? LOL
I am seeing it on my Dell laptop.
Remember to keep all things in perspective w/ IPIX both to the positive and the negative
Today's volume was only about $7000 worth of trades. Who really cares if the price goes up or down 10-15% as they will just reverse it next week to keep the price in the .03 range and they will keep it down that low until the DOD nasal spray is finalized IMO.
Some will ask who is "they" but everybody knows IPIX has been the target of major players who are making sure IPIX has little chance to succeed.
We have been so screwed by the FDA IMO that I view the OM P3 as another chance for FDA to manipulate the trial so that results are less than stellar. Some will call me a conspiracy freak but when it comes to the FDA I truly do believe they are controlled by BP.
I also don't have any positive vibes that a major buyout of IPIX is imminent or even being discussed. Not saying it couldn't be happening but nothing in our history to show such a powerful event should be expected, especially now when B hasn't been "proven" in any application yet.
My faith is all on the DOD and their need for a broad spectrum antiviral NOW. There data will also make any finagling by the FDA very suspect so it should greatly help B and IPIX move forward.
Alpha Sigma is a useless POS in my opinion so no movement forward on postsigmoid colitis gel/foam.
It was quite evident the OM data was good, not rocket science.
The Payer's Analysis was very good news and again not rocket science that it makes sense to do a P3 (at least to some interested party).
The problems are in the negotiations to put the potential partners and Leo on the same page. Seems this has been the case for everything to date dealing w/ Brilacidin. Is Leo asking way too much or are partners offering way too little? If they are close we may see something by end of year.
If they are not close time line goes out considerably. What makes me shake my head is that this is a billion dollar + need and yet not one partner to date seems to want to give squat for the partnership. Even giving IPIX a fair deal would seem to help the partner's bottom line considerably having this OM treatment.
My main question is if negotiating a deal is even in Leo's wheel house of expertise? To date I would say not likely to hell no. Is the new hire really a deal maker as some have extolled him to be as I have heard Leo hasn't even identified him as a business development pro to those Leo has talked to since the hire. Not trying to sow doubt here but I have heard Leo has become quite close-mouthed to everybody regarding IPIX events and he hasn't identified the new hire as to just what his duties are. Thus, I take everything with a grain of salt, even supposedly great or positive news.
Guess we wait and see if something comes about or if we stay in limbo adrift in a sea of great financial need for the company.
OM is the perfect application IMO for Brilacidin to become an approved drug. It has very decent revenue potential but nothing compared to those waiting in the wings (viral, fungal, IBD, anti-inflammatory, etc.), it seems right up Brilacidin's line of maximum effectiveness, there are no major competitors, etc. I sure hope both sides realize the importance of getting this done and a deal is made but I won't get excited until I see the deal is done. Until then just a nice pipe dream.
I question if any BP would give us any more than scraps in a partnership. Look at Merck, we double their fungal drug effectiveness and I bet they offer us just a few percentage points for a combo drug..
Not saying something couldn't happen, I just don't put much faith in BP either.
IMO our only hope of moving B forward is the military for the nasal broad spectrum antiviral of Brilacidin, U of Sao Paulo for the advancement of B as a fungicide due to the heavy incidence of fungal infections in S America, and possibly Europe for a partner that would help advance the inhaler form of B.
I have absolutely NO FAITH in the FDA allowing B to move forward per instructions from their masters, the BPs.
A BP should partner w/ IPIX in regards to fungicide investigation as B worked so well with their products and besides making their treatments so much more effective it would also also them to get new patent life for the drug combo.
I am not sure who in the US is working on the inhaler. That would be a wonderful development for the world but again I have no faith in anybody but the military at this time that is truly working to advance B as quickly as possible.
Heard in a roundabout way that JFM had pretty much moved on from IPIX so I wouldn't plan on much news from him. If we do get some posts down the line, great, but that would surprise me. He was a great contributor to the board.
I think of all the BILLIONS spent medical advancement in the US by other than BPs and yet nobody finds B attractive enough to get it out to the public. It is not as if they are being led down a phony path by IPIX claims, all the claims for B effectiveness are the result of governmental investigations and testing.
There's been plenty of talk for the last 4 to 5 months about how IPIX is on the verge of signing a deal of some sort and I don't see how anybody could possibly have any clue as to how far out a deal really is - simply my opinion.
I side with you as how would anyone outside of Leo know if a deal was made and he certainly wouldn't be telling anyone as that could lead to a jail sentence.
I firmly believe Brilacidin is advancing but not nearly as quickly as many surmise.
If it costs money he isn't doing it.
We now have 4 major avenues of moving IPIX forward in play:
1 DOD nasal spray of Brilacidin as a broad spectrum antiviral.
2 USP (Univ of Sao Paulo in Brazil) advancing B as a major fungicide.
3 Oral Mucositis moving forward into a Phase 3 trial
4 BeaMed laser investment
The problem we have is that none of these avenues have a responsibility to keep the public informed of their progress in regards to B.
DOD will take B thru a P1 and P2 trial on their own without FDA input but I don't think they have any legal obligation to keep the public informed of same. So who would actually make a PR as to when the nasal spray is ready for testing and the results of such testing? The upside here is that the DOD needs this medication ASAP and once they get it past P2 they will look quite hard at the FDA (IMO) if they then encounter large BS blocks in the road as to the P3.
Same with USP as to fungicide advancement. I would hope in Brazil, which has a lot of fungicide cases due to being so heavily covered in jungle terrain, that they could give the drug (or combo of drugs in conjunction with current authorized fungicidies) in a Compassionate Use form to patients prior to going thru all the bells and whistles of the 3 ring circus that is the FDA. But if they can't, who knows how long it will take?
OM P3 was supposed to have come about early 2022 as I recall and here we are sitting with squat to date. Who knows when this will finally get partnered allowing for some sort of advancement?
BeaMed is up in the air but thankfully this company is headed by 2 very successful BUSSINESSMEN that should be able to get it going thru the 510k pathway at a far greater speed than what we have come to find the norm w/ IPIX. From what I have been told, the lasers are already certified by the FDA so we are just talking about a new software program to get covered. No idea as to time here but at least I feel this avenue is in extremely good management hands.
Whatever the case for Brilacidin, we need 1 avenue certified by the FDA and that should allow the floodgates to open for many more. Hope our mgt keeps us alive and kicking until we reach this point.
One of the other benefits of B is that it appears to be able to combine with a great many other drugs to make them more efficient.
Lots of opportunities for BP to combine B with their drugs that are approaching the end of their patent life and allow for a new patent or patent extension I(I am not all that up on just how this works but I know it would benefit BP big time).
Brilacidin is finally getting known for being all we know it to be by outside researchers.
It is apparent to me that some BP will realize that with the outlandish potential B has in regards to infections, viruses, fungi, inflammatory issues, and other such matters that paying a hefty upfront price is still a steal as the revenue streams B will be attacking are such that it only has to succeed strongly in one revenue stream to make their investment a wise decision.
Many BPs are getting short on drugs making them money and B has to be quite an attractive answer to their needs.
This paper PRd today is impressive but not enough to get the price appreciation ball rolling IMO. The paper noting the broad spectrum viral workings of B should make the world of BP realize B will be a widely used drug. I don't believe any paper alone can do the trick but they sure lay the basis for BP to start making some realistic bids for B.
IMO we will start to greatly increase in share price when any of the following occur:
1) DOD picks B as their viral wide spectrum nasal remedy.
2) We partner Oral Mucositis with a noted BP and it works well.
3) Some BP comes in with a strong bid to partner the IBD arm.
IPIX has finally left the starting gate and is slowly gaining momentum. I believe by the end of 2023 we will be sitting in quite a different position than we are today. I only take it out this far as things always seem to move at a glacial pace for IPIX. I still believe IPIX allows a greater chance for wealth accumulation than most any other investment available. If I was young, I would acquire a nice position. As I am old, I need my current position to come around by the end of 2023 and am praying it gets done. I feel pretty good that this will occur.
Everything now is out of IPIX hands as ALL work on B is being done by others. As such, I don't see the current salary for Leo being justified and I certainly don't see any bonuses for anybody in mgt/board being merited either.
One would have thought with the testing to date someone would have found value in Kevetrin to pay a few million to continue testing (especially since oral form was already done and tox tests were 1/2 way completed).
Do believe stockholders deserve some sort ltr from Leo regarding this matter.
At inception, Dr. Frei, major voice in children's cancer at the time, was highly inclined as to the potential of K to treat many types of cancers and IPIX had one of the top patent attorneys do the work to make sure nobody could hijack the drug.
Hard to believe